MADISON, Wis., April 14, 2021 /PRNewswire/ -- Exact Sciences
Corp. (NASDAQ: EXAS) today announced that it has completed
its previously announced acquisition of Ashion Analytics,
LLC.
"As a leader in cancer testing, we're committed to providing
earlier answers and life-changing treatment guidance to support
patients along every step of their cancer journey," said
Kevin Conroy, chairman and CEO of
Exact Sciences. "With Ashion, we've added a talented team, a
CLIA-certified and CAP-accredited lab, deep sequencing
capabilities, and one of the most comprehensive genomic cancer
tests available on the market today with GEM ExTra®. This
expertise will be integral in helping us extend our leadership in
precision oncology and in serving more patients across the cancer
continuum, including therapy selection and minimal residual disease
testing."
Exact Sciences and The Translational Genomics Research
Institute (TGen) are expanding their multi-year collaboration to
further benefit from TGen and City of Hope's expertise in
developing better advanced cancer diagnostics and establishing the
clinical evidence necessary to support their adoption.
About Exact Sciences Corp.
A leading provider of
cancer screening and diagnostic tests, Exact Sciences relentlessly
pursues smarter solutions providing the clarity to take
life-changing action, earlier. Fueled by the success of Cologuard
and Oncotype DX, Exact Sciences is investing in its product
pipeline to take on some of the deadliest cancers and improve
patient care. Alongside its visionary collaborators and in
partnership with communities, Exact Sciences unites the best
resources to help advance the fight against cancer. For more
information, please visit the company's website
at www.exactsciences.com, or follow Exact Sciences on Twitter,
Facebook, or LinkedIn.
About TGen, an affiliate of City of Hope
Translational
Genomics Research Institute (TGen) is a Phoenix, Arizona-based nonprofit organization
dedicated to conducting groundbreaking research with life-changing
results. TGen is affiliated with City of Hope, a world-renowned
independent research and treatment center for cancer, diabetes and
other life-threatening diseases. This precision medicine
affiliation between City of Hope and TGen enables both institutions
to complement each other in research and patient care, with City of
Hope providing a significant clinical setting to advance scientific
discoveries made by TGen. TGen is focused on helping patients with
neurological disorders, cancer, diabetes and infectious diseases
through cutting-edge translational research (the process of rapidly
moving research toward patient benefit). TGen physicians and
scientists work to unravel the genetic components of both common
and complex rare diseases in adults and children. Working with
collaborators in the scientific and medical communities worldwide,
TGen makes a substantial contribution to help City of Hope's
patients through efficiency and effectiveness of the translational
process. For more information, please visit TGen's website
at www.tgen.org, or follow TGen
on Facebook, LinkedIn or Twitter
@TGen.
About City of Hope
City of Hope is an independent
biomedical research and treatment center for cancer, diabetes and
other life-threatening diseases. Founded in 1913, City of Hope is a
leader in bone marrow transplantation and immunotherapy
such as CAR T cell therapy. City of Hope's translational
research and personalized treatment protocols advance care
throughout the world. Human synthetic insulin, monoclonal
antibodies, and numerous breakthrough cancer
drugs are based on technology developed at the institution.
Translational Genomics Research Institute (TGen) became a
part of City of Hope in 2016. AccessHopeTM, a
wholly owned subsidiary, was launched in 2019, dedicated to serving
employers and their health care partners by providing access to
City of Hope's exceptional cancer expertise. A National Cancer
Institute-designated comprehensive cancer center and a founding
member of the National Comprehensive Cancer Network, City of Hope
is ranked among the nation's "Best Hospitals" in cancer by U.S.
News & World Report. Its main campus is located near
Los Angeles, with additional
locations throughout Southern
California and in Arizona.
For more information about City of Hope, follow us
on Facebook, Twitter, YouTube or Instagram.
Forward-Looking Statement
This news release contains
forward-looking statements concerning our expectations,
anticipations, intentions, beliefs or strategies regarding the
future. These forward-looking statements are based on
assumptions that we have made as of the date hereof and are subject
to known and unknown risks and uncertainties that could cause
actual results, conditions and events to differ materially from
those anticipated. You should not place undue reliance on
forward-looking statements. There can be no assurance that we will
be able to (i) realize the anticipated benefit from the acquisition
of Ashion, (ii) successfully commercialize GEM ExTra or (iii)
successfully develop or commercialize any products or services
utilizing the expected collaboration efforts with TGen or City of
Hope. Risks and uncertainties that may affect our forward-looking
statements are described in the Risk Factors sections of our most
recent Annual Report on Form 10-K and any subsequent Quarterly
Reports on Form 10-Q, and in our other reports filed with the
Securities and Exchange Commission. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
Exact Sciences Contacts:
Investor Contact:
Megan
Jones
mjones@exactsciences.com
608-535-8815
Media Contact:
Steph
Spanos
sspanos@exactsciences.com
608-556-4380
View original content to download
multimedia:http://www.prnewswire.com/news-releases/exact-sciences-completes-acquisition-of-ashion-analytics-llc-from-the-translational-genomics-research-institute-an-affiliate-of-city-of-hope-301268298.html
SOURCE EXACT SCIENCES CORP